4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

BTIG Research downgraded Alpha Teknova from Buy to Neutral

Stephens initiated coverage of Alpha Teknova with a rating of Overweight

Stephens & Co. initiated coverage of Alpha Teknova with a rating of Overweight and set a new price target of $27.00

Cowen & Co. initiated coverage of Alpha Teknova with a rating of Outperform

BTIG initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $26.00

10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

8-K - Alpha Teknova, Inc. (0001850902) (Filer)

EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)

S-3 - Alpha Teknova, Inc. (0001850902) (Filer)

8-K - Alpha Teknova, Inc. (0001850902) (Filer)

10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

8-K - Alpha Teknova, Inc. (0001850902) (Filer)

DEFA14A - Alpha Teknova, Inc. (0001850902) (Filer)

DEF 14A - Alpha Teknova, Inc. (0001850902) (Filer)

S-8 - Alpha Teknova, Inc. (0001850902) (Filer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

4 - Alpha Teknova, Inc. (0001850902) (Issuer)

Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to partic

HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow's cell therapies. As previously announced, Teknova and Plu

HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innova

Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue guidance of $39-42 million HOLLISTER, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2024. "I am very proud of our execution in 2024, across-the-board," said Stephen Gunstream, Pre

HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. Teknova will host a webcast and conference call on Tuesday, March 4, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you w

Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul

HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to partic

Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue guidance of $39-42 million HOLLISTER, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2024. "I am very proud of our execution in 2024, across-the-board," said Stephen Gunstream, Pre

HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. Teknova will host a webcast and conference call on Tuesday, March 4, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you w

Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul

Second quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024. "We delivered solid results across the board in the first half of 2024," said Stephen Guns

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market. Teknova will host a webcast and conference call on Tuesday, August 13, 2024, beginning at 5:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like t

SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

SC 13G - Alpha Teknova, Inc. (0001850902) (Subject)